Sodium Iodide

Summary

Sodium Iodide (CHEMBL1644695) is an approved small molecule; indicated across 2 conditions including st-elevation myocardial infarction and acute myocardial infarction.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 5
• Chemistry: 149.8942 Da · INa

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1644695
Name	Sodium Iodide
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	5238
ChEBI	CHEBI:33167
Molecular formula	INa
Molecular weight	149.8942
InChIKey	FVAUCKIRQBBSSJ-UHFFFAOYSA-M

SMILES: [Na+].[I-]

IUPAC name: sodium iodide

ChEBI definition: A metal iodide salt with a Na(+) counterion.

Also known as: Fdy-5301, Iodide (as sodium iodide), NSC-77388, Sodium iodide, sodium iodide, SID144211696, SODIUM IODIDE

Parent form; salt/anhydrous children: CHEMBL1201083, CHEMBL1201084, CHEMBL2105877, CHEMBL3707217

Patent coverage: 47,476 distinct patent families (131,627 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 118,220 (90%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
ST-elevation myocardial infarction	2	MONDO:0041656	EFO:0008585
acute myocardial infarction	2	MONDO:0004781	EFO:0008583

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE2	2
PHASE4	1
PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00638092	PHASE4	COMPLETED	A Randomised Controlled Trial of Iodide Supplementation in Preterm Infants Follow-up at 2 Years
NCT04837001	PHASE3	COMPLETED	Evaluation in STEMI Patients Using FDY-5301
NCT03470441	PHASE2	COMPLETED	A Study of Acute Myocardial Infarction Using FDY-5301
NCT04430283	PHASE2	TERMINATED	Evaluation of FDY-5301 in Major Trauma Patients in ICU
NCT02359279	Not specified	COMPLETED	Radiographic Contrast To Differentiate Cavitated From Non-cavitated Tooth Decay

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).